Monday, 23 Jul 2018

You are here

EULAR 2018 - Day 3 Report

Behcet’s Responds to Apremilast – We missed reporting this one on Wednesday when Hatemi et al presented the results of a phase 3 trial of apremilast (APR) vs placebo (PBO) in active Behcet’s with oral ulcers, with ≥3 OU at the start. BD patients (n-207) were randomized (1:1) to APR 30 mg BID or PBO (n=103) for 12 weeks, followed by a 52-week active-treatment extension.  The total number of Oral Ulcers was statistically significantly lower in the APR group compared with the PBO group. Numerically greater number of patients had resolution of genital ulcers at Week 12 in the APR group.  It appears this drug is headed to the FDA for decision later this year.

Biologics Do Not Differentially Affect TKR/THR Post-Operative Infection Rates  – a review of the claims data looked at over 11,000 RA patients on biologics (Abatacept, Adalimumab, Etanercept, Infliximab and fewer on Rituximab or Tocilizumab). (OP0228). The post-op hospitalized infection rate was 6.6 to 8.5% and was not significant between biologics (similar for the 30 day readmission rate). This was clearly different with steroid use which showed a dose related increased risk of hospitalized infection and 30 day readmission for infection, with a 2 fold increase risk for those receiving prednisone > 10 mg per day.  Similarly prosthetic joint infections were increased with increasing steroid use but were similar in frequency with biologics. Tocilizumab was associated with a higher risk of prosthetic infections, but this finding is less certain given the lower, limited number of TCZ treated patients in this cohort. (Correction: this article has been updated to reflect the correct abstract, OP0228. We apologize for any inconvenience.)

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Predictors of Methotrexate Non-Response

New research from a UK study suggests that nonresponse to oral or subcutaneous MTX was seen in 43% and is predicted by seronegativity, higher disease activity measures and higher anxiety scores.

Best of 2017: New EULAR Guidelines on Behçet's

At the EULAR 2016 meeting, new EULAR recommendations for the management of Behçet's disease (BD) were presented. These were developed by a multidisciplinary expert committee that reviewed the evidence from the medical literature and developed final set of 9 recommendations:

Canada Closer to Marijuana Approval

Reuters reports that Canada’s Senate on Thursday voted to legalize recreational marijuana, clearing a major hurdle that puts the country on track to become the first Group of Seven nation to permit national use of the drug.

Now the law and amendments go to the House of Commons who will need to decide on before the law can be passed.

Advance Practice Clinicians Proliferating in Specialty Practices

An analysis of SK&A outpatient provider files, covering 90% of physician practices in the United States, shows that between 2008 to 2016, there was a 22% increase in the employment of advanced practice clinicians (APCs) by specialty practices.  By 2016, 28% of all specialty practices employed APCs.

Trump Blasts Drug Makers on the Price of Drugs

Reuter's reports Friday that President Donald Trump blasted drugmakers and healthcare “middlemen” for making prescription drugs unaffordable for Americans. Nonetheless, many healthcare stocks rose as it became clear the administration had avoided taking aggressive and direct measures to cut drug prices.

Here are many New Sources on this developing story: